Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 2
2012 2
2013 3
2014 1
2016 1
2017 3
2018 1
2019 2
2020 5
2021 5
2022 5
2023 5
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP, Parikh R, Gunturu KS, Tariq RZ, Dani SS, Ganatra S, Nohria A. Patel RP, et al. Among authors: gunturu ks. Curr Oncol Rep. 2021 May 3;23(7):79. doi: 10.1007/s11912-021-01070-6. Curr Oncol Rep. 2021. PMID: 33937956 Free PMC article. Review.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators. Powles T, et al. Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051178 Clinical Trial.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
Osataphan S, Awidi M, Jan YJ, Gunturu K, Sundararaman S, Viray H, Frankenberger E, Mariano M, O'Loughlin L, Piper-Vallillo A, Stafford K, Kolnick A, Ghazalah H, Sehgal K, Patti ME, Costa D, Lam P, Rangachari D. Osataphan S, et al. Among authors: gunturu k. Lung Cancer. 2024 Dec;198:108023. doi: 10.1016/j.lungcan.2024.108023. Epub 2024 Nov 15. Lung Cancer. 2024. PMID: 39571252
Diagnosis and management of tumor lysis syndrome.
Puri I, Sharma D, Gunturu KS, Ahmed AA. Puri I, et al. Among authors: gunturu ks. J Community Hosp Intern Med Perspect. 2020 Jun 14;10(3):269-272. doi: 10.1080/20009666.2020.1761185. J Community Hosp Intern Med Perspect. 2020. PMID: 32850076 Free PMC article. Review.
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. Grossmann KF, et al. Among authors: gunturu ks. Cancer Discov. 2022 Mar 1;12(3):644-653. doi: 10.1158/2159-8290.CD-21-1141. Cancer Discov. 2022. PMID: 34764195 Free PMC article. Clinical Trial.
37 results